Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Home News & Resources Publications Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Read entire article